<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="5166">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03039686</url>
  </required_header>
  <id_info>
    <org_study_id>CN001-016</org_study_id>
    <secondary_id>2016-001654-18</secondary_id>
    <nct_id>NCT03039686</nct_id>
  </id_info>
  <brief_title>Clinical Trial to Evaluate the Efficacy, Safety, and Tolerability of BMS-986089 in Ambulatory Boys With Duchenne Muscular Dystrophy</brief_title>
  <official_title>A Randomized, Double Blind, Placebo-Controlled, Study to Assess the Efficacy, Safety, and Tolerability of BMS-986089 in Ambulatory Boys With Duchenne Muscular Dystrophy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bristol-Myers Squibb</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multi-center, randomized, double-blind, placebo-controlled study to assess the
      efficacy, safety and tolerability of two different weekly doses of BMS-986089 in ambulatory
      boys with Duchenne Muscular Dystrophy (DMD).
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">March 30, 2017</start_date>
  <completion_date type="Anticipated">July 30, 2020</completion_date>
  <primary_completion_date type="Anticipated">July 30, 2020</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Participant, Care Provider, Investigator, Outcomes Assessor</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in the 4 stair climb velocity in BMS-986089 treated participants.</measure>
    <time_frame>48 Week</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline in the 4 stair climb velocity in placebo treated participants.</measure>
    <time_frame>48 Week</time_frame>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">159</enrollment>
  <condition>Duchenne Muscular Dystrophy</condition>
  <arm_group>
    <arm_group_label>BMS-986089, dose 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Take BMS-986089 subcutaneously on specified days over a 48 week blinded period</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BMS-986089, dose 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Take BMS-986089 subcutaneously on specified days over a 48 week blinded period</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo solution taken subcutaneously on specified days over a 48 week blinded period</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>BMS-986089</intervention_name>
    <description>Take BMS-986089 subcutaneously on specified days over a 48 week blinded period</description>
    <arm_group_label>BMS-986089, dose 1</arm_group_label>
    <arm_group_label>BMS-986089, dose 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo for BMS-986089</intervention_name>
    <description>Take placebo subcutaneously on specified days over a 48 week blinded period</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosed with DMD by a blood test

          -  Able to walk without assistance

          -  Able to walk up 4 stairs in 8 seconds or less

          -  Weigh at least 15 kg (33 lbs)

          -  Taking corticosteroids for DMD

        Exclusion Criteria:

          -  Any behavior or mental issue that will affect the ability to complete the required
             study procedures

          -  Previously or currently taking medications like androgens or human growth hormone

          -  Use of a ventilator during the day

          -  Unable to have blood samples collected or receive an injection under the skin

        Other protocol defined Inclusion/Exclusion Criteria could apply.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>11 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bristol-Myers Squibb</last_name>
    <role>Study Director</role>
    <affiliation>Bristol-Myers Squibb</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Recruiting sites have contact information. Please contact the sites directly. If there is no contact information, please email:</last_name>
    <email>Clinical.Trials@bms.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>First line of the email MUST contain NCT# and Site #.</last_name>
  </overall_contact_backup>
  <link>
    <url>http://www.bms.com/studyconnect/pages/home.aspx</url>
    <description>BMS Clinical Trial Education Resource</description>
  </link>
  <link>
    <url>http://www.bms.com/clinical_trials/pages/investigator_inquiry_form.aspx</url>
    <description>Investigator Inquiry Form</description>
  </link>
  <link>
    <url>http://www.fda.gov/Safety/Recalls/</url>
    <description>FDA Safety Alerts and Recalls</description>
  </link>
  <link>
    <url>http://ctr.bms.com/ctd/start.do</url>
    <description>BMS Clinical Trial Information</description>
  </link>
  <verification_date>January 2017</verification_date>
  <lastchanged_date>January 31, 2017</lastchanged_date>
  <firstreceived_date>January 27, 2017</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>muscular dystrophy</keyword>
  <keyword>Duchenne's Muscular Dystrophy</keyword>
  <keyword>DMD</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Muscular Dystrophies</mesh_term>
    <mesh_term>Muscular Dystrophy, Duchenne</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
